Semaglutide, the active compound in Ozempic and Wegovy, has demonstrated weight loss of up to 15 percent in clinical trials
3,4 American Association of Clinical Endocrinology guidelines recommend treatment with GLP-1RA in T2DM patients with coexisting ASCVD, high-risk for ASCVD, heart failure, or chronic kidney disease regardless of their glycemic control due to their organ protective effects
The goal is not to scare patients away from treatment
While state Medicaid programs must cover nearly all Food and Drug Administration (FDA) approved drugs, a long-standing statutory exception allows states to choose whether to cover weight-loss drugs under Medicaid
Even though extensive research conducted over the last years did not unequivocally establish the etiology of depression, it revealed the complexity of its pathogenesis
The platform estimates one to two new GLP-1 drug launches per year beginning in 2026, with 39 GLP-1 medications currently in development